Evaluating the efficacy and safety of acotiamide in patients with esophagogastric junction outflow obstruction: study protocol for an investigator-initiated, multi-center, randomized, double-blind, placebo-controlled phase II trial

Trials

Study Protocol

Akiko Misumi¹  Hiroko Watanabe¹  Maya Suzuki¹  Junji Kishimoto¹  Toshio Uraoka²  Shiko Kuribayashi²  Katsuhiko Iwakiri³  Noriyuki Kawami³  Takatoshi Chinen⁴  Mitsuru Esaki⁴  Haruei Ogino⁴  Yoshihiro Ogawa⁴  Eikichi Ihara⁵  Noriaki Manabe⁶  Junichi Akiyama⁷ 

[1] Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan;Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan;Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan;Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan;Division of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan;

关键词: Esophagogastric junction outflow obstruction;    Acotiamide;    Esophageal motility disorders;    Achalasia;   

DOI  :  10.1186/s13063-023-07468-w

 received in 2023-05-03, accepted in 2023-06-20,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundWe have determined that the impaired accommodation of the lower esophageal sphincter (LES) underlies the pathogenesis of esophagogastric junction outflow obstruction (EGJOO). We have also found that acotiamide may treat EGJOO by improving impaired LES accommodation. The effects of acotiamide in patients with EGJOO need to be further confirmed in a prospective study.MethodsThis trial is a multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of acotiamide (300 mg/day or 600 mg/day) with those of a placebo in the treatment of patients with EGJOO. The primary endpoint will be the proportion of patients who report an improvement in symptom of food sticking in the chest after 4 weeks of treatment period 1. The secondary endpoints will be the proportion of patients with normalized integrated relaxation pressure (IRP), the value of change from baseline in the distal contractile integral, basal LES pressure, EGJOO–quality of life score, Gastrointestinal Symptom Rating Scale, and the correlation between IRP and each symptom score. During the 2-year trial period, 42 patients from five institutions will be enrolled.DiscussionThis trial will provide evidence to clarify the efficacy and safety of acotiamide as a treatment for patients with EGJOO. Acotiamide might help improve the quality of life of patients with EGJOO and is expected to prevent the progression of EGJOO to achalasia.Trial registrationThis study was approved by the Institutional Review Board (IRB) of Kyushu University Hospital as well as the local IRBs of the participating sites for clinical trials and registered in the Japan Registry of Clinical Trials (jRCT: 2071210072). The registration date is on October 11, 2021.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

13690_2023_1147_Article_IEq20.gif

13690_2023_1147_Article_IEq18.gif

13690_2023_1147_Article_IEq16.gif